These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16609301)

  • 21. The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio.
    Bode-Böger SM; Scalera F; Ignarro LJ
    Pharmacol Ther; 2007 Jun; 114(3):295-306. PubMed ID: 17482266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients.
    Mallamaci F; Benedetto FA; Tripepi G; Cutrupi S; Pizzini P; Stancanelli B; Seminara G; Bonanno G; Rapisarda F; Fatuzzo P; Malatino LS; Zoccali C
    J Hypertens; 2008 Sep; 26(9):1875-82. PubMed ID: 18698224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of endothelial-derived nitric oxide in hypertension and renal disease.
    Marin E; Sessa WC
    Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):105-10. PubMed ID: 17293684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
    Kielstein JT; Zoccali C
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):609-15. PubMed ID: 18941355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?
    Kielstein JT; Frölich JC; Haller H; Fliser D
    Nephrol Dial Transplant; 2001 Sep; 16(9):1742-5. PubMed ID: 11522849
    [No Abstract]   [Full Text] [Related]  

  • 26. Relationship between chronic kidney disease prevalence and end-stage renal disease risk.
    Hallan SI; Vikse BE
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):286-91. PubMed ID: 18408480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitric oxide and the renal hemodynamic response to proteins.
    King AJ
    Semin Nephrol; 1995 Sep; 15(5):405-14. PubMed ID: 8525142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis.
    Grasemann H; Al-Saleh S; Scott JA; Shehnaz D; Mehl A; Amin R; Rafii M; Pencharz P; Belik J; Ratjen F
    Am J Respir Crit Care Med; 2011 May; 183(10):1363-8. PubMed ID: 21278301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nitric oxide and renal functions in liver cirrhosis.
    Türkay C; Yönem O; Arikan O; Baskin E
    Turk J Gastroenterol; 2004 Jun; 15(2):73-6. PubMed ID: 15334313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms.
    Caplin B; Nitsch D; Gill H; Hoefield R; Blackwell S; MacKenzie D; Cooper JA; Middleton RJ; Talmud PJ; Veitch P; Norman J; Wheeler DC; Leiper JM
    Kidney Int; 2010 Mar; 77(5):459-67. PubMed ID: 20010544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Asymmetric dimethylarginine: predictor of cardiovascular diseases?].
    Németh B; Kustán P; Németh Á; Lenkey Z; Cziráki A; Kiss I; Sulyok E; Ajtay Z
    Orv Hetil; 2016 Mar; 157(13):483-7. PubMed ID: 26996894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.
    Zoccali C
    J Hypertens; 2006 Apr; 24(4):611-9. PubMed ID: 16531785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New pathways to renal damage: role of ADMA in retarding renal disease progression.
    Ueda S; Yamagishi S; Okuda S
    J Nephrol; 2010; 23(4):377-86. PubMed ID: 20349427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?
    Kielstein JT; Fliser D; Veldink H
    Semin Dial; 2009; 22(4):346-50. PubMed ID: 19708979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Regular exercise training decreases asymmetric dimethylarginine after kidney transplantation].
    Teplan V; Mahrová A; Svagrová K; Racek J; Gürlich R; Teplan V; Senolt L; Stollová M
    Vnitr Lek; 2012 Sep; 58(9):640-6. PubMed ID: 23094808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of nitric oxide synthesis by L-arginine supplementation in renal disease: is it good or bad?
    De Nicola L; Minutolo R; Bellizzi V; Andreucci M; La Verde A; Cianciaruso B
    Miner Electrolyte Metab; 1997; 23(3-6):144-50. PubMed ID: 9387105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of asymmetric dimethylarginine in cardiorenal syndrome.
    Ueda S; Yamagishi S; Yokoro M; Okuda S
    Curr Pharm Des; 2014; 20(14):2448-55. PubMed ID: 23844812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease.
    Fliser D
    J Nephrol; 2010; 23(4):369-76. PubMed ID: 20349425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting on Asymmetric Dimethylarginine-Related Nitric Oxide-Reactive Oxygen Species Imbalance to Reprogram the Development of Hypertension.
    Tain YL; Hsu CN
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27918455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.
    Landim MB; Casella Filho A; Chagas AC
    Clinics (Sao Paulo); 2009 May; 64(5):471-8. PubMed ID: 19488614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.